Zacks Small Cap Issues Negative Forecast for ENSC Earnings

Ensysce Biosciences, Inc. (NASDAQ:ENSC) – Zacks Small Cap dropped their Q1 2025 earnings estimates for shares of Ensysce Biosciences in a report released on Tuesday, March 11th. Zacks Small Cap analyst B. Sorensen now expects that the company will post earnings of ($4.50) per share for the quarter, down from their previous estimate of ($3.84). The consensus estimate for Ensysce Biosciences’ current full-year earnings is ($8.33) per share. Zacks Small Cap also issued estimates for Ensysce Biosciences’ Q2 2025 earnings at ($4.50) EPS, Q3 2025 earnings at ($3.00) EPS, Q4 2025 earnings at ($1.81) EPS, FY2025 earnings at ($14.81) EPS and FY2026 earnings at $42.42 EPS.

Ensysce Biosciences Stock Down 14.5 %

Shares of Ensysce Biosciences stock opened at $3.90 on Thursday. Ensysce Biosciences has a twelve month low of $2.12 and a twelve month high of $14.67. The company has a 50-day simple moving average of $6.38 and a two-hundred day simple moving average of $6.49. The stock has a market capitalization of $5.09 million, a price-to-earnings ratio of -0.14 and a beta of 0.64.

Ensysce Biosciences (NASDAQ:ENSC) last announced its earnings results on Monday, March 10th. The company reported ($2.90) EPS for the quarter, missing the consensus estimate of ($2.74) by ($0.16). The company had revenue of $1.30 million for the quarter, compared to the consensus estimate of $0.25 million. Ensysce Biosciences had a negative return on equity of 292.81% and a negative net margin of 179.26%.

Institutional Trading of Ensysce Biosciences

A hedge fund recently bought a new stake in Ensysce Biosciences stock. Adage Capital Partners GP L.L.C. bought a new stake in Ensysce Biosciences, Inc. (NASDAQ:ENSC) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 50,000 shares of the company’s stock, valued at approximately $407,000. Adage Capital Partners GP L.L.C. owned approximately 3.82% of Ensysce Biosciences at the end of the most recent quarter. Institutional investors own 5.63% of the company’s stock.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.